NCT03422744

Brief Summary

There is an interest in characterazing asymptomatic peripheral lung lesions beacause they could be an early form of neoplasm. These lesions are invisible in the endoscopic exam, so the samples must be made with a guiding technique. The trans bronchial biopsy after tracking by radial echo-endoscopic miniprobes can be used to collect tissue sample. When no diagnosis is made with this technique, the attitude can be discussed between different option: follow up versus an other sampling technique (transthoracic ponction, surgery,...). In this study the investigators will study the interest of a sampling guided by fluoroscopy after a negative sampling guided by radial echo-endoscopic miniprobe. People presenting with a peripheral lung lesion, invisible with a classical endoscopy, will be included after they sign an informed consent. The bronchoscopy will be executed after a local anesthesia and if there are no visible endobronchial lesions, the radial EBUS mini-probe will be used. If these samples give an anatomopathologic diagnosis consistent with the clinical context, no other exam will be proposed. If there isn't a diagnosis after this first exam, a second exam will be proposed to the participants including an histologic smear, a trans bronchial biopsy and a fine needle aspiration under fluoroscopic guidance.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3

participants targeted

Target at below P25 for not_applicable lung-cancer

Timeline
Completed

Started Aug 2017

Longer than P75 for not_applicable lung-cancer

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 3, 2017

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

October 6, 2017

Completed
4 months until next milestone

First Posted

Study publicly available on registry

February 6, 2018

Completed
4.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2022

Completed
Last Updated

January 18, 2023

Status Verified

January 1, 2023

Enrollment Period

5.2 years

First QC Date

October 6, 2017

Last Update Submit

January 16, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percentage Definitive anatomopathological diagnosis

    Percentage Definitive anatomopathological diagnosis obtained via the pathological exam of microscopic evaluation, immunostaining and/ or molecular analysis)

    1 week

Study Arms (1)

patient with peripheral lung lesion

EXPERIMENTAL

Patient presenting a peripheral lung lesion seen at Ct-scan but invisible at simple endoscopy. Intervention : trans bronchial biopsy guided by echo-endoscopic miniprobes. Intervention: If first intervention doesn't give a diagnosis we get cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control

Procedure: trans bronchial biopsy guided by echo-endoscopic miniprobesProcedure: if first one negative: samples under fluoroscopic control

Interventions

We get a sample trough transbronchial biopsy guided by echo-endoscopic miniprobe.

patient with peripheral lung lesion

If no diagnosis with first intervention we get a second sample by cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control

patient with peripheral lung lesion

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients presenting a peripheral lung lesion having given their approval

You may not qualify if:

  • Lung lesion who according to ct Scan has a greater diameter lesser than 10 mm
  • Ground glass lesion
  • Lesion that are suspected to be a bronchopneumonia
  • Contra-indication for endoscopic exam ( uncontrolled hypoxia, hypercapnia, sympotmatic bronchial hyperreactivity, recent myocardial infarction, heart failure)
  • contra-indication for a transbronchial biopsy ( coagulapathy iatrogenic or not, recent uptake of anitaggregant medicines)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHu Saint Pierre

Brussels, 1000, Belgium

Location

Related Links

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Marie Bruyneel, MD PhD

    CHU St Pierre

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator, pneumology

Study Record Dates

First Submitted

October 6, 2017

First Posted

February 6, 2018

Study Start

August 3, 2017

Primary Completion

September 30, 2022

Study Completion

September 30, 2022

Last Updated

January 18, 2023

Record last verified: 2023-01

Locations